Spots Global Cancer Trial Database for Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
Official Title: A Phase I Study of SGN-40 (Anti-huCD40 mAb), Lenalidomide (Revlimid®, cc 5013), and Dexamethasone in Patients With Multiple Myeloma (MM)
Study ID: NCT00525447
Conditions
Study Description
Brief Summary: This is a Phase I, open-label, multi-dose trial to define the MTD and tolerability of a regimen including lenalidomide, dexamethasone, and intravenous SGN-40 in patients with relapsed multiple myeloma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Rocky Mountain Cancer Center, Denver, Colorado, United States
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Nebraska Methodist Hospital, Omaha, Nebraska, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Weill Medical College of Cornell University, New York, New York, United States
Avera Cancer Institute, Sioux Falls, South Dakota, United States
Baylor University Medical Center, Dallas, Texas, United States
Contact Details
Name: Nancy Whiting, PharmD
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
